Live Breaking News & Updates on டச்சு துணிகர முயற்சி
Stay updated with breaking news from டச்சு துணிகர முயற்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional £20 million in a Series B2 financing round. Having demonstrated proof of efficacy in patients with refractory or unexplained chronic cough i, NeRRe will now continue the clinical development of orvepitant in chronic cough caused by IPF, a rare type of interstitial lung disease ii. A dominant symptom of this severe progressive fibrotic pulmonary disease, in a high proportion of these terminally ill patients, is an uncontrolled, persistent, and disabling cough. ....
NeRRe Therapeutics raises £20 million in a Series B2 globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
NeRRe Therapeutics raises £20 million in a Series B2 financing round streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
VectorY Raises €31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Forbion Expands Team with New General Partner Tuesday, 18 May 2021 09:00 Hits: 862 NAARDEN, The Netherlands, May 18, 2021 / B3C newswire / Forbion, a leading European life sciences venture capital firm, is pleased to announce that Jasper Bos, PhD, a former Merck executive, has joined its growing investment team as General Partner for the firm’s Growth Fund. Before joining Forbion’s Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, the venture arm of pharmaceutical giant Merck, which he joined in 2009. At M Ventures, he led a team of twenty-one investment professionals and with a fund size of €400 million invested in over 50 portfolio companies spanning biotech, life sciences tools, and tech companies with investment activities ranging from seed-stage to cross-over and IPO. ....